Author: OurCrowd

[Alloy Therapeutics in BusinessWire] Tahoe Therapeutics and Alloy Therapeutics to form joint venture and develop first-in-class antibody-drug conjugates for hard-to-treat cancers

BOSTON & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers. Read more...

Read More

[Polarisqb in Quantum Computing Report] Polaris Quantum Biotech study demonstrates quantum advantage over generative AI in drug discovery

Polaris Quantum Biotech (PolarisQB) has released a comparative study indicating that its Quantum-Aided Drug Design (QuADD) platform, powered by D-Wave Quantum Inc.’s annealing technology, significantly outperforms classical Generative AI in lead identification for drug discovery. The study, currently a preprint on ChemRxiv, compared QuADD to the Bond and Interaction generating Diffusion model (BInD), a representative AI-based diffusion algorithm. The findings suggest that quantum annealing can reduce the timeline for selecting pre-clinical molecular candidates from months to hours while delivering higher-quality results. Watch...

Read More